The development and subsequent deterioration of diabetic foot ulceration (DFU) is a common occurrence across all healthcare divides, concerning all patient groups, age, gender and social environments. It increases demand on clinical resources and creates unnecessary hardship for patients. Chronic DFU is challenging to prevent and notoriously difficult to manage owing to the complex nature of the patient and the disease itself. The improvement of oxygenation to many chronic wound groups is gaining momentum across wound care; particularly in those wounds such as DFU that present with circulatory, oxygen-deficient scenarios. Method: a descriptive evaluation was undertaken in an acute clinical setting where a spray solution containing purified haemoglobin was used in a cohort of 20 patients who presented with chronic (>12 weeks) DFU. Standard wound care was undertaken by 18 health professionals with no changes to products, devices or practice before evaluation. All wounds received the addition of the product on eight set occasions over a 4-week period and the resulting data correlated in regards to the set outcomes of wound surface area reduction, ease of use, adverse events and patient acceptability. Results: at 4 weeks all wounds had demonstrated positive wound reduction, there were no adverse events, all patients and clinicians found the product acceptable and easy to use. Interestingly, although not a set outcome, all wounds commenced the evaluation with wound-bed slough present and at 4 weeks 100% were deemed slough free. At a further 4-week review no patients wounds had regressed. Conclusion: the incorporation of a haemoglobin spray solution within this cohort of DFU resulted in a positive improvement in wound healing and slough elimination. Further work in this area is recommended to increase the evidence.
Topical haemoglobin spray for diabetic foot ulceration
I t is estimated that 1 in 20 people had been diagnosed withdiabetesintheUKupto2012,thoughthisfigure doesnotacknowledgethosepatientsyettobeidentified (Diabetes UK, 2012) . Hex et al (2012) suggested an annualhealthcarespendof£1billionforpeoplewithtype 1 diabetes and £8.8 billion for those with type 2 diabetes, expectedtoriseyear-on-yearacrosstheUK.
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Inassociationwithdiabetes,thereisalsoanongoingincrease in the incidence of foot lesions/ulcers, which affect one in 10 patients and, according to Sharp (2013) , represent one of the most common reasons for admission to a healthcare setting.Diabeticfoot ulceration(DFU)presentsasignificant financialburdenfortheNHSwithanestimatedspendofup to£661 millionannually,representing0.7%ofthetotalNHS healthcareallocation (Kerr,2011) .
With regard to DFU aetiology, Boulton et al (2005) suggested prevalence rates of up to 42% for neuropathic disease, up to 23% for vascular insufficiency and up to 77% for those patients who would progress to surgical amputation. Patients with diabetes account for up 50% of all amputations (Ahmad et al, 2014) with the majority of these patients, around 6000 annually, presenting with foot ulcerationaccordingtotheNationalDiabetesSupportTeam (2008) . Surgical amputation is estimated to cost the NHS up to £76 million (Kerr, 2011) , representing 0.06% of the NHS annual budget of £121 billion (Harker, 2012) with manyoperationsdeemedpreventableandthereforeavoidable (DiabetesUK,2012) . CliniciansencounterDFUinthediabeticpopulationon a daily basis with ulceration proving notoriously difficult to heal, resulting in infection, extensive tissue damage, amputation and long-term disability (Edmonds, 2007) . Evaluation and review of new and innovative products or interventions is therefore essential if clinicians are to keep abreastofmanagingthiswoundgroupeffectively.
DFU and oxygenation
Diabetesoccurswhenthereisinadequateuptakeofglucose by the cells of the body resulting in raised blood glucose levels (Pocock and Richards, 2006) . Insulin, the hormone produced in the pancreas, regulates the release and storage ofenergyfromfood.Highplasmaglucoselevelscausedby diabetes can damage blood vessels and nerves resulting in ineffective reduction in circulating oxygen and deranged sensation (Vuolo,2009 Diabetes increases the risk of foot ulceration, which is oftenchronicinnature,duetomacroandmicro-angiopathy; ischaemia alone or in conjunction with varying levels of neuropathic nerve damage. Impairment and dys-regulation occurwithinthewound-healingprocessatbothcellularand molecularstages (Rafehietal,2011) .
Oxygen is an essential component of the wound-healing process. (Norris,2014) .Tissuethathashadaninsultandbegins thewoundhealingprocesswillautomaticallyhaveanincreased demandinthetissuesfortheiroxygendeliverycapacityand relyonthisprocesstoenabletissuetotravelthroughthekey stagesofinflammation,proliferationandmaturation (Flanagan, 2000) .Thebody'stissueshavenocapacityforretainingoxygen molecules and therefore require a consistent delivery along withnutrientsandotheragentsatvaryinglevelsondemand if wound healing is to occur effectively (Timmons, 2006) . Consequently, chronically oxygen-depleted cells at micro andmacrolevelshavedevastatingeffectsonvulnerabletissue, often resulting in deterioration, disfigurement and disability, particularly within the population of patients with diabetes (Dow, 2001) . Oxygenation is therefore imperative, either systemicallyortopically,inthewound-healingprocess.
Topicaloxygenationoftissuesisnotanewpractice,with clinicians recognising across many specialities the benefits andeffectivenessofthistherapy (LadizinskyandRoe,2010; Norris,2014; Winfeld,2014; Tickle,2015) .Bothhyperbaric oxygen therapy (HBOT) and topical oxygen therapy are interventions that can be implemented to support and aid wound healing (Tickle, 2015) . Topical haemoglobin treatments are designed to permit haemoglobin-mediated oxygendiffusioninthewoundbedasanaqueousmedium, improvingwoundhealingstates (Arenbergerovaetal,2013) .
Granulox
Granulox is a topical oxygen therapy comprising a haemoglobin spray for use on those wounds that are deemedchronicinnature.Itsactionpurportstothebinding and releasing of oxygen from the normal atmosphere onto the wound-bed surface, improving the oxygenation of the wound tissues through the process of diffusion, consequentially improving and supporting wound healing (Norris,2014; Tickle,2015) .Thetherapyrequiresverylittle training for its use, has no reported negative side effects to date and can be used by both clinicians and patients alike. The product is approved for multi-use as a non-woundcontact spray, to be applied at least every 72 hours on all woundsdeemedchronicinnature,presentfor12weeksor more (Arenbergerovaetal,2013) .
Granulox is deemed unsuitable for use with certain disinfectants (such as hydrogen peroxide or chlorhexide), or proteolytics as these can impair its effectiveness, where infectionispresent,andinthosepatientswhoarepregnant orlactatingowingtoalackofsignificantdataintheseareas. Wound beds must be clean and void of infection before application if the product is to be applied to the optimum environment.
Notable positive outcomes have emerged from work undertaken byArenberger et al (2011) (2014) on chronic wounds/compression and Budd-Chiari syndrome and recent clinical pilots using topical haemoglobin spray therapy on leg ulcers (Norris, 2014) and pressure ulcers (Tickle, 2015) and showed distinctly positive results.All of the authors promote the positive outcomes of increased healingpotential,woundreductionandnonegativereactions, buildinguptheevidenceacrossthechronicwoundarena.
Methodology
A single acute centre descriptive evaluation was undertaken to explore the efficacy of Granulox spray, with the primary outcome set as percentage reduction in wound surface area after 4 weeks' treatment with Granulox and secondary outcomesofpatientacceptability,adverseeventsandeaseofuse.
Inclusioncriteriawereageover18years,aSite,Ischemia, Neuropathy,BacterialInfection,AreaandDepth(SINBAD) scoremaximumof2 (Table 1) ,anddiabeticfootulcerlocated below the ankle.The SINBAD score of 2 was chosen as patients scoring 2 and below have fewer risk factors to inhibithealing,thosescoring3oroverusuallyhavevascular insufficiencyandoneortwootherwound-healingissuesthat wouldimpairtheeffectivenessofanyproductthatisplaced onthewoundbed.Exclusioncriteriarelatedtothosepatients that presented with infected ulcers, who were receiving systemicantibiotictherapyand/orcorticosteroids,thatwere pregnant or actively lactating, that had an ankle-brachial pressure index (ABPI) below 0.5 or toe pressure below 70 mmHgorHbA1c(glycatedhaemoglobin)measurement over10or86 mmol/litreandaSINBADscoreof3ormore.
Inthecourseoftheevaluation,20patientswhopresented tothedepartmentwithchronicDFUfor12weeksormore whomettheinclusioncriteria,andwhoverballyconsented following verbal explanation and review of the product and information leaflet, were treated with Granulox and 
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monitored over a 4-week period. Each patient received the same standard of care that they entered the evaluation with,sothattheonlyvariablewastheadditionofthespray product. Pre-evaluation care included soft silicone foams (adhesive/non-adhesive) hydrofibre adhesive foams, gentle adhesive foams, retention bandage, and the continuation of off-loading boots and shoes. The wound data was collated using the recognisedAppliedWound Management Assessment documentation (Gray et al, 2005; Wounds UK, 2009 )whichisthestandardwoundcaredocumentationused inthetrust. During the evaluation period all patients continued to have their dressings changed twice a week with the Granulox administered each time. Data collected related to wound size, exudate levels, consistency of same standards of care, percentage of slough, granulation and epithelium present. The products were applied either by the patient independently (75%) under clinical observation (following a visual demonstration in simple terms by the nurse or healthcareassistant)ortheclinician(25%),withtheclinician documenting the relevant data sets at each dressing change in the same designated treatment area (all dressing changes occurred in the acute setting). The author observed the dressing changes weekly and cross-checked the data for accuracy and to enable collection of both patient and clinician'sexperiencethroughouttheprocess.Atweeks1and 3,eachpatientandclinicianwasaskedverbally,onascaleof 1beingdifficultto5beingeasy,howtheyfelttheproduct was to use and on acceptability to the patient, a scale of 1 not acceptable to 5 very acceptable. Ethical approval was notrequired,inlinewithtrustpolicywithregardtoclinical reviewofCE-markedproducts.Informedverbalconsentwas documentedbytheclinicianinrelevantnotes.
Results
Thesettingwasonesingleacutesitewith20patientswho presentedwithchronicDFUof12weeks'standingormore overtheperiodofFebruarytoMarch2015.All20 patients who met the criteria were recruited and underwent the addition of Granulox to their care regimen over a 4-week period. 
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PRODUCT EVALUATION ©2015MAHealthcareLtd 20%, pedal 15%, and distal phalanges 5%.The mean time for woundsbeingpresentpriortotheapplicationofGranuloxwas 10 months (range: 3 months to 18 months).With regard to off-loadingdevicesusedbeforeandcontinuingthroughoutthe evaluationperiod,5%hadafibreglassheelcast,5%Cascadefoam boot,15%AirCastboot,15%Darcoshoe,15%ProCareshoe, totalling11patients(55%)usingoff-loadingequipment. At 4 weeks the DFU exudate levels demonstrated a significantreductionacrossallpatientswithanendpointof 70% increase in patients with no exuding wounds, a 10% reduction in wounds with mild exudate, a 30% reduction in moderate exuding wounds and a complete resolution of all wounds that commenced the therapy within the severegroup (Table 3) . Althoughnotapresetobjective,itis interestingtonotethatallofthe20patientshadpresented withvaryinglevelsofwoundbedslough,rangingfrom10% to 100%, at day 1 and at week 4 all 20 patients' wounds were slough free (Figure 1) . No debridement process at all occurredduringtheevaluation,onlybasicwoundcleaning withsalinewhereneeded. Woundreductionwaspositiveinalloftherecruitswith 5ofthepatients(25%)goingontofullepithelialisationat thelastwoundassessment( Table 4) .Thisisnotsurprising clinically within this patient group as each of these 5 patients had a shorter duration of wound pre-evaluation, were in the lower age bracket (except patient 9) and all werefreeofneuropathyandvasculardeficiency.Onlyone patient (Patient 19) of the group who had reached full epithelialisationatweek4hadusedanoff-loadingdevice while others with devices had varying levels of wound closure,suggestingthebenefitscannotbesolelyrelatedto dressingproductsoroff-loadingequipment. 
Patient and clinician satisfaction
Of the 20 patients, 75% after limited demonstration were able to apply Granulox independently as part of their own dressing regimen within the clinical area observed by the clinician,25%ofpatientshadeitheramentalhealthorphysical disability that prevented them from using the spray and so cliniciansappliedthespray-threepatientsoutofthefivehada confirmeddiagnosisofdementiawithcognitivedisfunctionof understanding,memorylossetc,whiletheothertwopatients had end-stage rheumatoid arthritis and could not hold the spraywiththeirfingersorpressthebuttontoreleaseproduct. Allthecliniciansinvolvedintheevaluation,18intotal,both healthcare assistants and registered nurses, were satisfied with the use and ease of the product scoring a 5 stating it was extremely easy to use. Of the 15 patients who administered theirownGranulox,10foundtheproductextremelyeasyto usegradingitasa5patientswhile5foundtheproducteasy to use grading it as a 4. (Figure 2) A total of 4 out of the 18 clinicianswereslightlynervousatfirstinusingtheproduct:
'I am wary a little, as it doesn't look like a dressing or wound care product' (Registered nurse) Despitethisall18clinicianswerehappytocontinuetouse theproductthroughouttheevaluation.
Regardingthewrittendocumentprovidedtothegroups,two patientshighlightedthattheinformationleafletinthepackwas smallinprintandalargerprintspecificallyforthemwouldhave beenuseful.Thiswasalsoemphasisedbythreeoftheclinicians who felt a simple diagrammatic leaflet for patients would aid understanding of the product's function and benefits over the detailedversionavailable.Overall,allofthecliniciansandpatients praisedtheproductandwishedtocontinuewithitthroughout the4-weekevaluationperiod.
'Simple-I didn't think it would work as it's just clear water to me, and it's so easy to spray on' Patient 9, who went on to full epithelialisation.
Discussion
Wound tissue is dependent on a consistent influx of oxygenation to enable the process of healing to occur (Flanagan, 2000) . Hypoxic tissue will fail to regenerate, stay fixed in the inflammatory stage, and be prevented from movingalongthewound-healingcontinuumincreasingthe riskofbacterialinfectionandtissuedisfiguration (Sen,2009) . ThissmallevaluationexploredtheapplicationofGranulox haemoglobinspraywithintheacutesettingovera4-week period for those patients who presented with chronic diabetic foot ulcers despite clinicians using best practice according to NICE (2011) guidelines. All 20 patients demonstrated varying levels of progressive wound healing, wound reduction, elimination of slough and a positive reductioninexudatelevels.Theresultsofthisstudysupports the European work carried out on lower limb extremities byArenbergeretal(2011)whofoundencouraginghealing rates of 93% with topical oxygenation therapy versus 7% withoutat6monthsinasingle-site,randomisedcontrolled trial) and Arenbergerova et al (2013) who found 53% average improvement with haemoglobin vs 21% average worsening without, in a prospective randomised control study in 72 non-healing or worsening venous leg ulcers receivingstandardcarewithcompression.WorkintheUK carried out by Norris (2014) on venous leg ulcers and Tickle(2015) onpressureulcers,agreedwithotherstudies in showing positive benefits in wound size reduction, exudate minimisation and the improvement in visible presence of slough with the use of topical oxygenation donationonchronicwounds.
As an adjunct to the clinical benefits of Granulox, this evaluationtouchedontheclinicians'andpatients'experience of the product's use over a 4-week period. Due to physical or mental health issues not all of the patients were able to use the product independently and required clinical input inthedressingregimens.Theactualproductcontaineritself wouldthereforerequiremodifyingifitsuseacrossallpatient groupsistobemaximised.Patientswitharthritisfoundthe containerandbuttondifficulttomanipulateduetorestricted movementintheirfingers-perhapsalargernozzleorbutton couldbeadaptedfortheiruse.
Despite this, all recruited patients and participating cliniciansfoundtheproducteasytouseandwerehappyto continueitsapplicationovertheevaluationduration.Patients continued to use the product in the clinical area after the 4-week period; the author monitored them at 2-week intervalsforanother4weeksandnopatientsregressedwith regardtowoundhealing.
Strengths and limitations of evaluation
The evaluation cohort group represented only a small sample of patients who presented with chronic DFU that hadbeenpresentfor3monthsormoreinanacutesetting. The product's effects over a longer period of time, with increasedapplications,andonpatientswithaSINBADscore of 3 or more have not been addressed and so the benefits to the wider population are not known. However, the data collected acknowledge various ages, equal gender numbers, the most common anatomical sites for DFU, and varying comorbidities,whichenrichesandstrengthenstheevidence. There were no patient drop-outs, the data were collected andcross-checkedbytheauthor;theresultsdemonstrateda PRODUCT EVALUATION ©2015MAHealthcareLtd positivesetofoutcomesaddingtoandmirroringresultsfrom current available literature. Although clinical efficacy and patient/clinicianexperiencehavebeenbasicallyexploredwith positive outcomes, addressing a more in-depth experiential aspectalongsidetheeconomicandstrategicelementswould expandtheknowledgeofthisproduct'sbenefitwithinhealth care, gaining increased credibility of oxygen therapy within theDFUpopulation.
Conclusion
Emphasis on DFU prevention and management 'gold standard' of care must incorporate a full multidisciplinary approach that includes effective patient education, accurate assessment by the appropriate clinician and subsequent correct diagnosis, effective management planning and re-evaluation (O'Loughlinetal,2010) .Thepatientandcarer are absolutely vital to this team approach if prevention of ulcerationistobemaintainedandanymanagementstrategies put in place are consistent and complied with (Sign, 2013) . Wound management using innovative therapies is one key partofthatholisticcarepackageforthosepatientswhohave developed DFU. This evaluation, although only small in sample size, is worthy of consideration by clinicians in managementofthoseDFUsthataredeemedchronicdespite 'gold standard' interventions being in place. Further comprehensive evidence gathering is required in moving forward to ensure clinicians are fully informed as to the benefits across all wound groups of this innovative oxygendeliverytherapy.
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